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Lymphocyte recovery and clinical response in multiple myeloma patients
receiving interferon CX2f after intensive therapy
BC Millar, JBG Bell and RL Powles
Section ofAcademic Haematology, The McElwain Laboratories, Institute ofCancer Research and the Royal Marsden NHS Trust,
Sutton, Surrey, UK.
Summary The recovery of immunoregulatory cells in the peripheral blood of patients with multiple myeloma
receiving maintenance therapy with interferon a2 (IFN-Ot2p) after intensive therapy with high-dose melphalan
and autologous bone marrow or peripheral blood stem cell rescue was studied. IFN-a2p significantly inhibited
the recovery of CD3+, CD4+, CD8+, CD56+/CD3- and CD16+/CD3- lymphocytes compared with
numbers found in patients who had no further post-transplant treatment, but had no effect on the recovery of
CDl9+ cells. Among patients who did not receive IFN-a2f, the number of CD8+, CD56+/CD3- and
CD16+CD3- lymphocytes recovered to values similar to normal volunteers with increasing time after
intensive therapy, however the number of CD4+ cells remained significantly below levels found in normal
volunteers. Although CD16+/CD3- and CD56+/CD3- cell numbers were reduced in patients receiving IFN-
a2f,, natural killer (NK) activity was not effected. The levels of soluble interleukin 2 receptor (sIL-2R) were
similar in all patients and IL-2 was not detected in any patient. At the time of writing, of the total of 69
patients, seven have relapsed, of whom three were receiving IFN-a2fl, however there was no correlation
between the absolute numbers of any lymphocyte subset with imminent relapse. The data suggest that the
recovery of a specific lymphocyte subset(s) in peripheral blood is unlikely to be associated with the
maintenance of response after intensive therapy.
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Multiple myeloma (MM) is a disease of the B-cell lineage and
remains incurable. Encouraging results from two clinical
studies suggest that maintenance therapy with interferon a2,
(IFN-a2fp) after intensive therapy with autologous bone
marrow rescue (ABMR) (Attal et al., 1992; Cunningham et
al., 1993) increases the duration of response and may prolong
survival (Cunningham et al., 1993). Since this therapeutic
benefit is confined to patients who have had a complete
response to treatment, it has been suggested that IFN-X2, is
only effective in patients who have had a substantial
reduction of the tumour burden (Attal et al., 1992). Thus
far, there has been no indication that IFN-X2,0 improves the
clinical status after intensive therapy, suggesting that the
mechanism(s) involved in its therapeutic efficacy is concerned
with the maintenance of tumour homeostasis rather than
direct cytotoxicity.
The existence of monoclonal gammopathies of undeter-
mined significance (MGUS) and plateau phase MM shows
that monoclonal B cells can be kept under homeostatic
control in vivo. In the case of plateau phase disease, this has
been attributed to complex interactions between the
malignant clone and the immune system (Joshua, 1988).
Several lines of evidence suggest that the evolution of the
disease is influenced by the behaviour of immunoregulatory
cells. Idiotype-reactive T cells have been found in MM
patients with early stage disease (Dianzani et al., 1988;
Osterborg et al., 1991) and high levels of interluekin 2 (IL-2)
have been correlated with prolonged survival (Cimino et al.,
1990). In contrast, high levels of soluble IL 2 receptor (sIL-
2R) in peripheral blood correlated with active disease (Vacca
et al., 1991) and low CD4+ cell numbers have been associated
with both advanced clinical disease and shorter survival (San
Miguel et al., 1992).
Massaia et al. (1993) have shown that activation of CD3+
lymphocytes from MM patients in vitro results in greater
production of IFN-y than that produced from normal donor
cells. This may have an association with putative tumour
control in vivo since IFN-y, as well as IL-2, induces the
differentiation of allergen-specific T cells in vitro to TH-1
clones and is induced by IFN-oa (Parronchi et al., 1992).
As well as T cell-mediated immunoregulation, there is
evidence that natural killer (NK) and lymphocyte-activated
killer (LAK) cells may play a role in the regulation of MM.
Although the number of precursors of cytotoxic cells may be
reduced in patients with MM (Massaia et al., 1988) and LAK
activity of peripheral blood T- and non-T lymphocytes is
reduced compared with normal donors (Massaia et al., 1989),
both cellular and humoral effector mechanisms are retained
that can regulate the behaviour of MM cells in model systems
(Abbas, 1979; Rohrer and Lynch, 1979). Despite a reduction
in NK activity in patients with advanced MM (Osterborg et
al., 1990) a signifigant increase has been found in patients
with early stage disease (Gonzalez et al., 1992) and in patients
following response to treatment or during plateau phase
(Osterborg et al., 1990). In vitro exposure of peripheral blood
mononuclear cells from MM patients to IFN-a2fl increases
NK activity (Uchida et al., 1984) and in vivo administration
of IFN-a2p increased NK activity in patients given the
cytokine as sole treatment (Einhorn et al., 1982).
The aim of this study was to determine whether the
recovery of one or more lymphocyte subsets associated with
immune regulation is enhanced in patients receiving high-
dose melphalan (HDM) in combination with ABMR or
peripheral blood stem cell rescue (PBSCR) followed by
maintenance therapy with IFN-CX2p and may serve as a
measure of the therapeutic effect(s) of the cytokine.
Comparisons have been made between patients who are
receiving IFN-a2f with those who have had no further
treatment after intensive therapy and with normal volun-
teers. In addition, the clinical response of patients to HDM
followed by IFN-aC2 has been monitored to determine
whether the cytokine improves the anti-tumour effect of
intensive therapy.
Materials and methods
Clinical samples
Samples (10 ml) of clotted and heparinised peripheral blood
were taken at out-patient clinics from patients and normal
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volunteers after informed consent and approval by the local
Royal Marsden Hospital Ethics Committee. All patients had
received treatment with one of two conditioning regimens,
either CY-VAMP [i.v. infusion of vincristine (0.4 mg) and
doxorubicin (9 mg m-2) over 24 h for 4 days with bolus of
methylprednisolone (1.5 g i.v. or orally for 5 days) plus
cyclophosphamide (500 mg i.v. bolus on days 1, 8 and 15)] or
VERCY-VAMP (vincristine, doxorubicin, methylpredniso-
lone and cyclophosphamide (doses as before) plus verapamil
(10 mg i.v. over 24 h for 5 days) followed by HDM either
200 mg m-2 with ABMR or PBSCR or 140 mg m-2 alone.
Patients who had ABMR were given methylprednisolone
(1 g m-2 daily for 5 days) after HDM. In the total group of
69 patients, two received high-dose busulphan (HDBu)
(16 mg kg-' body weight over 4 days) with ABMR, seven
were given IFN-o2 after CY-VAMP, one received HDM and
two received HDM with methylprednisolone without rescue.
When their leucocyte count was greater than 3 x 109 1-' and
platelets were greater than 100 x 109 1-1, patients were given
IFN-a2, (Intron-A, Shering-Plough) at 3 x 106 U m-2 sub-
cutaneously three times weekly until relapse.
The distribution of treatment protocols of patients who
had received IFN-a2 for more or less than 12 months was
similar to that of patients who had no further treatment in
each group.
Clinical status
A complete remission (CR) was defined as the absence of
measurable paraprotein and bone marrow infiltration by
myeloma cells of <5%. A partial response (PR) was defined
as a paraprotein level reduced by 50% and improvement in
all other clinical features sustained for greater than 1 month.
Flow cytometric analysis
All blood samples were counted and used for flow cytometric
analysis within 2 h of collection. Aliquots of 50 jMl were
dispensed into tubes with 10 ,ul of ready-conjugated antibody
agitated on a mixer and incubated at 4°C for 20 min. Lysis
solution (1 ml) (Ortho-Diagnostics, UK) was added to each
tube and incubation continued at room temperature for
10 min. The tubes were transferred to an ice bath and
analysed immediately. The antibodies used were mouse anti-
human CD45-FITC/CD14-RPE (Sigma, UK), CD4-FITC/
CD8-RPE (Sigma, UK), CD3-FITC, CD19-RPE, CD16-RPE
and CD56-RPE (Becton Dickinson, UK).
Analysis was done using an Ortho Cytoronabsolute
(OrthoDiagnostics, UK) with gating for lymphocytes. The
machine was calibrated before use with normal donor blood
that had been assessed for the different count. Calibration for
the lymphocyte gate ensured that >99% of the gated cells
were lymphocytes. Data with experimental samples were
collected in list mode file and analysed using the software
package supplied by the manufacturer. All subsequent
calculations were based on the total white cell count assayed
by Coulter Counter to provide absolute counts of individual
lymphocyte subsets.
NK activity
Freshly harvested lymphocytes obtained by Ficoll-Hypaque
separation of whole blood (Boyum, 1968) followed by
removal of phagocytic cells with carbonyl iron were used as
effector cells. The percentage of lymphocytes in the resulting
suspensions ranged from 85% to 99%. The K562 cell line
was used as target cells for NK activity. Cells were labelled
with 200 pCi 10-6 cells of 5"Cr (1 mCi ml-' Amersham
International, UK) in a volume of 200,l. Samples were
tested at four effector-target (E/T) cell ratios (60:1, 30:1,
15: 1 and 7.5: 1) using 5000 K562 cells per well in a total
volume of 200,l in 96-well microtitre plates. Samples were
assayed in triplicate. The cell mixtures were incubated for
18 h at 37°C. The radioactivity in the supernatant was
analysed in a gamma counter (Hydragamma 16, Innotron,
UK). Spontaneous release was determined by incubation of
5"Cr-labelled cells with medium alone. Maximum release was
measured by incubating the cells with lysis buffer (20 mM
Hepes pH 6.9, 5 mM potassium chloride, 5 mM magnesium
acetate, 1 mM DTT and 0.5% Nonidet 140). The percentage
of 5'Cr released was calculated from the formula;
% release=
(experimental 51Cr release - spontaneous 51Cr release) 100
(total 5lCr release - spontaneous 51Cr release
Absolute numbers of CD16+/CD3- and CD56+/CD3-
lymphocytes were calculated after depletion of phagocytic
cells using flow cytometry as above. The cells were labelled
with CD45-FITC/CD14-RPE, CD3-FITC/CD16-RPE and
CD3-FITC/CD56-RPE.
Detection of IL-2 and sIL-2R
Samples of clotted blood were separated and the serum
stored at -200 until use. IL-2 and IL-2R were measured
using enzyme-linked assays (Quantikine, R & D Systems,
USA, and Boehringer Mannheim Biochemica, UK, respec-
tively). Assays were performed in accordance with the
manufacturer's instructions.
Statistics
Data were analysed using a non parametric Mann-Whitney
U-test for significance. P-values from two-tailed Mann-
Whitney U-tests are given in the text.
Results
Lymphocyte analysis
The clinical status of MM patients used in this study at the
time of examining the lymphocyte subsets is shown in Table
I. Although total white cell counts (WBCs) remained
significantly lower in patients who received IFN-X2,i for
prolonged periods after intensive therapy than in patients
who had no further treatment (P<0.02) or normal volunteers
(P<0.0002), this was not a reflection of a general inhibition
of recovery among each of the lymphocyte subsets (Table II).
Despite a significant reduction in B-cell numbers in all
patients after HDM, IFN-a2 had no effect on their recovery
compared with that seen among patients who had no further
treatment, and numbers returned to levels similar to those in
normal volunteers 12 months after HDM. In contrast, IFN-
a2p inhibited the recovery of CD3+, CD4+/CD3+, CD8+/
CD3+, CD16+/CD3- and CD56+/CD3- lymphocytes. Since
HDM also inhibited the recovery of CD4+/CD3+ T cells, the
poor recovery in this subset was augmented by IFN-a2f. The
data are summarised in Table II.
NK activity
NK activity correlated with absolute numbers of CD16+/
CD3- lymphocytes (r=0.616) (Figure 1) but not with
CD56+/CD3- cells (data not shown). Although absolute
numbers of both CD16+/CD3- and CD56+/CD3- lympho-
cytes remained low in patients receiving long-term treatment
with IFN-a2,i (Table II), there was no significant difference
between NK activity in patients or normal volunteers. The
mean lytic activity was 60% +6.2% in normal volunteers,
57.8% +4.2% in patients who had no further treatment and
51.75% +6.0% in patients on IFN-CX2fi (Figure 2).
sIL-2R and IL-2
Analysis of sIL-2R in serum from the patients who were
taking IFN-a2 compared with those who were not showed
that there was no significant difference between the levels
compared with that reported for normal volunteers. TheImmune recovery in myoloma patients
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Table I Clinical status of multiple myeloma patients treated with HDM/ABMR or PBSCR with or without maintenance therapy with
interferon a2b
Median time after Median time on Change in clinical Time ofstatus
HDM in months interferon a2p in Clinical statusa at time of testing status to present change after
(range) months (range) CR PR NC PD (July 1995) HDM
No interferon 522 3.5 NAt 1 5 3 1 PR-CR
group < 12 months (1-10) CR-PD 6 months
(n=10) PR-.PD 11 months
No interferon 12fl 47 NA 6 2 1 1 CR-*PD 61 months
group > 12 months (20-103) PR-+PD 107 months
(n= 10)
Interferon 52# group 5 3 11 11 6 0 PR-.CR
< 12 months (2-13) (0.5-12) PR-+CR
(n=28) NC-+CR
CR-+PD 6 months
CR-PD 9 months
PR-+PD 12 months
Interferon 52# group 46 27 11 6 3 1 No change in status
> 12 months (21-102) (13-70) of any patient
(n =21)
aCR, complete remission; PR, partial response; NC, no change after disease progression; PD, progressive disease (samples taken on day this was
identified). NA, not applicable.
Table II Comparison of surface epitopes in peripheral blood from normal donors with multiple myeloma patients treated with HDM/ABMR
or PBSCR with or without maintenance therapy with interferon-o2p at time intervals of 1-12 months and more than 12 months therapy
MM patients without IFN therapy MM patients given IFN therapy
Normal donors 1-12 months after > 12 months after 1-12 months on IFN > 12 months on IFN
(n=10) HDM (n=10) HDM (n= 10) (n=28) (n=21)
WBC 7.43 ±0.60 4.47+0.50 6.60±0.87 3.98+0.34 4.51 +0.32a
CD19+ 0.221 ±0.043 0.056±i. lgb 0.396 + 0.092 0.100+0.016 0.275 + 0.038
CD3+ 1.506+0.181 0.959+0.196 1.252+0.232 0.572 +0.037c 0.612 ±0.062c,d
CD16+/CED3- 0.179 +0.034 0.147 +0.049 0.193 +0.039 0.058 ±0.010 0.079±0.01Oe
CD56+/CD3- 0.329 +0.035 0.243 ±0.060 0.342 +0.068 0.115 + 0.015 0.204+0.022f
CD8+ 0.610+0.094 0.741 +0.158 0.724±0.156 0.402+0.032 0.305 0.0369
CD4+ 0.894+0.128 0.218 ±0.044 0.528 +0.093' 0.175 + 0.016 0.306 +0.032)
Results are given as absolute counts x 106 ml-1 (mean ±s.e.) ap < 0.0002 vs normal donors; P< 0.02 vs patients who had no further treatment
(NFT). bp <0.005 vs normal donors. CP<0.00001 vs normal donors. dp < 0.01 vs NFT. ep<0.02 vs normal donors. fP< 0.01 vs normal donors.
sP <0.005 vs normal donors. P <0.01 vs NFT. hp<0.00005 vs normal donors. 'P <0.05 vs normal donors.JP <0.02 vs NFT.
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Figure 1 Correlation of NK activity with absolute cell numbers
of CD16+/CD3- cells. 0, Normal volunteers; A, myeloma
patients on interferon a2p; A, myeloma patients not on interferon
a2f. NK activity is expressed as per cent lysis of 5000 51Cr-
labelled K562 cells.
mean level was 116.7+10.1 pmol I-' in patients receiving the
cytokine compared with 109.4 + 15.6 pmol 1-' in patients
who had no further treatment. IL-2 was not detected in
serum from any patient.
Clinical response
At the time of writing, 7/69 patients have relapsed within 6
months after examining their lymphocyte subsets, three of
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Figure 2 Comparison of NK activity in lymphocytes from
normal volunteers (0), myeloma patients on maintenance
therapy with interferon a2fl (A) and myeloma patients not
having maintenance therapy (A). NK activity is expressed as
per cent lysis of 5000 51Cr-labelled K562 cells; bar indicates mean
value.
whom were receiving IFN-a22. Although CDl9+ cell numbers
were lower in patients who relapsed subsequently, this was
not statistically significant. There was no correlation between
absolute numbers of other lymphocyte subsets among
patients who relapsed and those in patients who remain in
remission, irrespective of treatment with IFN-02f6*
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Diss
Although IFN-z2 has been used as maintenance therapy
after HDM for more than 6 years at the Royal Marsden
Hospital, the mechanism by which it regulates the prolifera-
tion of MM remains elusive. Examination of peripheral
blood samples after short (median time, 3 months) and long
(>12 months) exposure to IFN-i2 failed to identify the
enhanced recovery of a specific lymphocyte subset(s) which
might be a prognostic indicator for the anti-proliferative
effect of IFN-2.
Several authors have reported that continuous treatment
with IFN-z2 suppresses the peripheral blood WBC but that
recovery is rapid following cessation of treatment (Klinge-
mann et al., 1991). Reduced numbers of most lymphocyte
subsets contributed significantly to the delayed recovery of
the WBC in patients receiving IFN-i22 in addition to a long-
time inhibitory effect on the recovery of CD4- cell caused by
therapy (Bergmann et al., 1984). However, despite the
reduction in B cell numbers in all patients during the first
12 months after intensive therapy, their subsequent recovery
was not inhibited by IFN-o2 and cell numbers were similar
to those in normal volunteers at longer time intervals.
Previous studies have considered the role of immunor-
egulatory cells as prognostic indicators in untreated patients
with MM (Massaia et al., 1988, 1989) and the effects of IFN-
z2 on these cells in vitro (Uchida et al., 1984) or as a single
agent in vivo (Einhorn et al., 1982). The association of low
numbers of CD4+ lymphocytes with poor prognosis
(Bergmann et al., 1984) is clearly inappropriate as a criterion
of imminent relapse after intensive therapy, since their
recovery is known to be inhibited by chemotherapy
(Bergmann et al., 1984). In our patients, the delayed
recovery of CD4+ lymphocytes was increased by IFN-2
whereas the number of CD8+ cells was similar to those of
normal volunteers in patients who had no further treatment
within 12 months after intensive therapy. These data suggest
that despite the differential sensitivity of CD4+ and CD8+
lymphocytes to chemotherapy they are equally sensitive to
the anti-proliferative effects of IFN-2.
Although increased numbers of activated NK cells have
been found in the peripheral blood of untreated patients with
early stage disease (Osterborg et al., 1990; Gonzalez et al.,
1992), there was no indication that the magnitude of the
IFN--2rinduced enhancement of NK activity correlated with
clinical response to IFN-x2p (Einhorn et al., 1982). While the
latter study questions the role of NK cells in vivo in response
to IFN-:zv it is unlikely to be comparable with mechanisms
that are operable after intensive therapy. In a study in which
IFN-a2 was given to patients early after allogeneic
transplantation for advanced haematological diseases, NK
function was low before IFN and was not improved with the
cytokine (Klingemann et al., 1991), however the report took
no account of absolute numbers of NK cells. Although
recovery of the two major NK subsets, CD16-/CD3- and
CD56 /CD3- cells, was delayed in our patients receiving
IFN-a2 compared with patients who had no further
treatment, there was no difference in NK activity measured
by the lysis of K562 cells between patients and normal
donors. The data suggest that if NK cells have a role in
mediating tumour homeostatis in vivo after intensive therapy,
the efficacy of this mechanism may be lower in patients
receiving IFN-x2, because of fewer NK cells.
Given that MM is a disease of the B-cell lineage, the
recovery of B-cells in patients receiving IFN-xX raises
questions concerning both the putative stem cell in MM as
well as the mechanism by which tumour homeostasis is
achieved. Montes Borinaga (1993) showed that MM cells can
be cultured in vitro from patients receiving IFN-z2 as
maintenance therapy during remission after HDM/ABMR
suggesting that the effect of the cytokine in vivo is likely to be
cytostatic rather than cytocydal. Although the stem cell in
MM has not been identified several authors agree that it is
likely to arise after class-switching immediately before or at
the level of the memory B-cell (Ralph et al., 1993; Sahota et
al., 1994). The failure of neutralising antibody to IFN-:, to
persist in patients receiving the cytokine as maintenance
therapy led to the suggestion that memory B-cells may not be
involved (Millar and Bell, 1995). An alternative conclusion
could be that the proliferation and maturation of memory
cells may be inhibited in patients receiving the cytokine.
Despite our failure to identify a particular lymphocyte subset
in the peripheral blood that may effect tumour homeostasis,
we cannot exclude the possibility that changes may have
occurred in the milieu of the bone marrow or lymph nodes
that might account for inhibition of tumour cell proliferation.
Although sequestration of cytotoxic T cells and/or NK cells
to those sites may be responsible for localised control, the
relapse of three patients while receiving IFN-22 within 6
months of HDM with PBSCR suggets that the efficacy of
such a control mechanism would require a fine balance
between the residual tumour burden and the anti-tumour
effect of the cytokine.
The lack of correlation between absolute numbers of
lymphocyte subsets with relapse may be indicative of an
alternative mechanism dependent on changes in the cytokine
profile at specific sites within the bone marrow or lymph
nodes. There is increasing evidence that the cytokine profile
of the natural immune response probably determines the
phenotype of the specific immune response (Romagini, 1992).
For example, Thl (which produce IL-2 and IFN-y) and Th2
(which produce IL-4 and IL-5) lymphocytes are associated
with markedly different functions whereas ThO cells show an
unrestricted lymphokine pattern (Firestein et al., 1989).
Although IFN-a,2 promotes the differentiation of allergen-
specific T cells into Thl instead of Th2 clones (Parronchi et
al., 1992), IL-2 was not detected in the serum from any
patient, neither were the levels of sIL-2R different from those
in patients who did not receive the cytokine. However, the
net effect of INF-z2 in vivo may result in the localised release
of INF-y and IL-2 by different T cell subsets depending on
their proximity to cells that can respond and may be
insufficient to be detected in serum.
In conclusion, there was no enhanced recovery of a
particular lymphocyte subset(s) in peripheral blood samples
that may account for the anti-tumour effect of IFN-22 as
maintenance therapy. It seems likely that the anti-prolifera-
tive effect of the cytokine is determined by events that occur
at localised sites within the bone marrow or lymph nodes and
that such events are dependent critically on the residual
tumour mass.
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